Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include AS-3201, ranirestatum, (Spiro(pyrrolidine-3, 4′(1’H)-pyrrolo(1, 2-a)pyrazine)-1′, 2, 3′, 5(2’H)-tetrone, 2′-((4-bromo-2-fluorophenyl)methyl)- and (3R)-). Its PubChem CID is 153948.
Ranirestat
| CAS No | 147254-64-6 |
|---|---|
| Molecular Formula | C17H11BrFN3O4 |
| Molecular Weight | 420.2 g/mol |
| Synonyms | (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
The listed CAS number is 147254-64-6.
The listed molecular formula is C17H11BrFN3O4.
The listed molecular weight is 420.2 g/mol.
(3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone.
The source lists AS-3201, ranirestatum, (Spiro(pyrrolidine-3, 4'(1'H)-pyrrolo(1, 2-a)pyrazine)-1', 2, 3', 5(2'H)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)- and (3R)-).